Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Dyadic International Inc
DYAI | US
1.11
USD-0.05
-4.38%
DYAI | US
About Dyadic International Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.11
Open
1.15
High
1.19
Low
1.10
Dyadic International Inc. a biotechnology platform company develops produces and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research development and commercial activities for the development and manufacturing of human and animal vaccines and drugs such as virus-like particles protein antigens ferritin nanoparticles monoclonal antibodies bi/tri-specific antibodies fab antibody fragments Fc-fusion proteins biosimilars and/or biobetters and other therapeutic enzymes and proteins. The company offers DYAI-100 SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals S.L.U. as well as co-development and marketing agreement with Fermbox Bio Inc to design Develop and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter Florida.
View LessDYAI | US
Risk
78.0
Sharpe
-0.72
Luna's Score
30/100
Recommendation
Sell
Luna says (DYAI | US)
What's Working
Low Market Beta (-0.4 to 0.8)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
87.0%1 month
78.0%3 months
64.0%6 months
74.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
15.82
Price to book
10.51
Debt to equity
1.76
Debt to assets
0.52
Ent. to EBITDA
-2.93
Ent. to rev.
15.95
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
32.72M
MarketCap(USD)
32.72M
Div. yield
-
Op. margin
-528.50
Erngs. growth
-
Rev. growth
-53.90
Ret. on equity
-127.38
Short ratio
5.33
Short perc.
0.67
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.27
Range1M
0.32
Range3M
0.65
Volumes: Market Activity
Rel. volume
0.71
Price X volume
26.42K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.93 | 0.53 | Cheaper |
| Ent. to Revenue | 15.95 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 10.51 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 64.02 | 72.80 | Par |
| Debt to Equity | 1.76 | -1.23 | Expensive |
| Debt to Assets | 0.52 | 0.25 | Expensive |
| Market Cap | 32.72M | 3.66B | Emerging |
